VERRICA PHARMACEUTICALS INC (VRCA) Forecast, Price Target & Analyst Ratings
NASDAQ:VRCA • US92511W2070
5.21 USD
-0.12 (-2.25%)
Last: Mar 5, 2026, 01:09 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VERRICA PHARMACEUTICALS INC (VRCA).
Forecast Snapshot
Consensus Price Target
$16.83
+ 223.03% Upside
Next Earnings Forecast
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$0.81
Revenue Estimate4.616M
ChartMill Buy Consensus
81.82%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$16.83
Upside
+ 223.03%
From current price of $5.21 to mean target of $16.83, Based on 11 analyst forecasts
Low
$10.10
Median
$18.36
High
$21.00
Price Target Revisions
1 Month
0.00%
3 Months
1.02%
Price Target Summary
11 analysts have analysed VRCA and the average price target is 16.83 USD. This implies a price increase of 223.03% is expected in the next year compared to the current price of 5.21.
The average price target has been revised upward by 1.02% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.82%
VRCA was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about VRCA.
In the previous month the buy percentage consensus was at a similar level.
VRCA was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-18 | Brookline Capital | Upgrade | Hold -> Buy |
| 2025-05-14 | Needham | Reiterate | Hold -> Hold |
| 2025-04-09 | Needham | Reiterate | Hold -> Hold |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-03-12 | Needham | Reiterate | Hold -> Hold |
| 2024-12-20 | Needham | Reiterate | Hold -> Hold |
| 2024-11-06 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-11-05 | Needham | Reiterate | Hold |
| 2024-11-05 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-10-21 | TD Cowen | Maintains | Buy -> Buy |
| 2024-10-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-10-03 | Needham | Downgrade | Buy -> Hold |
| 2024-10-02 | Brookline Capital | Downgrade | Buy -> Hold |
| 2024-08-15 | Needham | Maintains | Buy -> Buy |
| 2024-08-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-05-16 | Needham | Reiterate | Buy -> Buy |
| 2024-05-14 | Needham | Maintains | Buy -> Buy |
| 2024-05-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-10 | Needham | Reiterate | Buy -> Buy |
| 2024-03-01 | Needham | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-15 | Jefferies | Reiterate | Buy -> Buy |
| 2023-11-10 | Needham | Maintains | Buy -> Buy |
| 2023-10-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-23 | Needham | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$0.81
Revenue Estimate4.616M
Revenue Q2Q1,241.86%
EPS Q2Q66.24%
Number of Analysts7
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-31.64%
EPS (1 Month)
0.00%
EPS (3 Months)
-33.13%
Next Earnings Summary
VRCA is expected to report earnings on 3/9/2026. The consensus EPS estimate for the next earnings is -0.81 USD and the consensus revenue estimate is 4.62M USD.
The next earnings revenue estimate has been revised downward by 31.64% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 9.03M -24.75% | 5.124M -43.26% | 7.566M 47.66% | 35.782M 372.93% | 28.682M -19.84% | 58.242M 103.06% | 151.32M 159.81% | 172.79M 14.19% | 198.39M 14.82% | 229.76M 15.81% | 243.27M 5.88% | 254.44M 4.59% | |
| EBITDA YoY % growth | -20.84M 32.05% | -62.672M -200.73% | -64.875M -3.52% | -31.518M 51.42% | -25.092M 20.39% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -21.29M 31.12% | -63.222M -196.96% | -65.836M -4.13% | -10.522M 84.02% | -23.784M -126.05% | -6.754M 71.60% | 67.371M 1,097.43% | 84.813M 25.89% | 105.16M 23.99% | 127.65M 21.39% | 129.13M 1.16% | 135.2M 4.70% | |
| Operating Margin | -235.77% | -1,233.84% | -870.16% | -29.41% | -82.92% | -11.60% | 44.52% | 49.08% | 53.01% | 55.56% | 53.08% | 53.14% | |
| EPS YoY % growth | -7.90 38.76% | -14.60 -84.81% | -15.40 -5.48% | -1.56 89.89% | -1.21 22.55% | -0.19 83.93% | 6.22 3,310.53% | 3.47 -44.26% | 3.77 8.82% | 3.88 2.70% | 3.72 -3.95% | 3.57 -4.11% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.81 66.24% | -0.51 49.00% | -0.39 -2,038.00% | -0.35 -1,073.00% | -0.31 61.60% |
| Revenue Q2Q % growth | 4.616M 1,241.86% | 5.712M 66.92% | 6.936M -45.39% | 7.65M -46.67% | 9.384M 103.29% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.171M 45.52% | -6.834M 15.94% | -5.763M -481.66% | -2.703M -266.13% | -5.151M 16.53% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.73%
EPS Next 5 Year
17.35%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
90.54%
Revenue Next 5 Year
83.00%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
VERRICA PHARMACEUTICALS INC / VRCA Forecast FAQ
What is the average price target for VERRICA PHARMACEUTICALS INC (VRCA) stock?
11 analysts have analysed VRCA and the average price target is 16.83 USD. This implies a price increase of 223.03% is expected in the next year compared to the current price of 5.21.
Can you provide the upcoming earnings date for VERRICA PHARMACEUTICALS INC?
VERRICA PHARMACEUTICALS INC (VRCA) will report earnings on 2026-03-09, after the market close.
Can you provide the consensus estimates for VERRICA PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of VERRICA PHARMACEUTICALS INC (VRCA) is -0.81 USD and the consensus revenue estimate is 4.62M USD.
Can you provide the expected long term growth rate for VERRICA PHARMACEUTICALS INC stock?
The expected long term growth rate for VERRICA PHARMACEUTICALS INC (VRCA) is 90.54%.